{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:21:37Z","timestamp":1719620497092},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,27]]},"DOI":"10.7759\/cureus.63332","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T05:04:15Z","timestamp":1719551055000},"source":"Crossref","is-referenced-by-count":0,"title":["Response of FGFR-2 Positive Adenoid Cystic Carcinoma to Futibatinib: A Case Report"],"prefix":"10.7759","author":[{"given":"Yoan E","family":"Rodriguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maham","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Badillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augusto","family":"Villegas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilmarie","family":"Guzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/7401458","article-title":"Adenoid cystic carcinoma of salivary glands: a ten-year review and an assessment of the current management, surgery, radiotherapy, and chemotherapy","volume":"2023","author":"Saleh E","year":"2023","unstructured":"Saleh E, Ukwas A. Adenoid cystic carcinoma of salivary glands: a ten-year review and an assessment of the current management, surgery, radiotherapy, and chemotherapy. Int J Otolaryngol. 2023, 2023:7401458. 10.1155\/2023\/7401458","journal-title":"Int J Otolaryngol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.18632\/oncoscience.581","article-title":"Adenoid cystic carcinoma of the head and neck - treatment strategies of a highly malignant tumor with variable localizations","volume":"10","author":"Dudde F","year":"2023","unstructured":"Dudde F, Henkel KO, Barbarewicz F. Adenoid cystic carcinoma of the head and neck - treatment strategies of a highly malignant tumor with variable localizations. Oncoscience. 2023, 10:27-9. 10.18632\/oncoscience.581","journal-title":"Oncoscience"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.12005","article-title":"Clinical experience of 23 cases of adenoid cystic carcinoma of the external auditory canal","volume":"20","author":"Jiang X","year":"2020","unstructured":"Jiang X, Jia L, Zhang X, Zhong C, Tang F, Chen X, Yuan W. Clinical experience of 23 cases of adenoid cystic carcinoma of the external auditory canal. Oncol Lett. 2020, 20:144. 10.3892\/ol.2020.12005","journal-title":"Oncol Lett"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh M","year":"2024","unstructured":"Katoh M, Loriot Y, Brandi G, Tavolari S, Wainberg ZA, Katoh M. FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions. Nat Rev Clin Oncol. 2024, 21:312-9. 10.1038\/s41571-024-00869-z","journal-title":"Nat Rev Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0115-y","article-title":"Fibroblast growth factor receptors as treatment targets in clinical oncology","volume":"16","author":"Katoh M","year":"2019","unstructured":"Katoh M. Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat Rev Clin Oncol. 2019, 16:105-22. 10.1038\/s41571-018-0115-y","journal-title":"Nat Rev Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal L","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, et al.. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023, 388:228-39. 10.1056\/NEJMoa2206834","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05066-5","article-title":"Truncated FGFR2 is a clinically actionable oncogene in multiple cancers","volume":"608","author":"Zingg D","year":"2022","unstructured":"Zingg D, Bhin J, Yemelyanenko J, et al.. Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. Nature. 2022, 608:609-17. 10.1038\/s41586-022-05066-5","journal-title":"Nature"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.14639\/0392-100X-N1729","article-title":"Adenoid cystic carcinoma. An indolent but aggressive tumour. Part B: treatment and prognosis","volume":"41","author":"Cant\u00f9 G","year":"2021","unstructured":"Cant\u00f9 G. Adenoid cystic carcinoma. An indolent but aggressive tumour. Part B: treatment and prognosis. Acta Otorhinolaryngol Ital. 2021, 41:296-307. 10.14639\/0392-100X-N1729","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"ref9","article-title":"Systemic therapies for salivary gland adenoid cystic carcinoma","volume":"11","author":"Sahara S","year":"2021","unstructured":"Sahara S, Herzog AE, N\u00f6r JE. Systemic therapies for salivary gland adenoid cystic carcinoma. Am J Cancer Res. 2021, 11:4092-110.","journal-title":"Am J Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2646","article-title":"Safety profile and adverse event management for futibatinib, an irreversible FGFR1-4 inhibitor: pooled safety analysis of 469 patients","volume":"30","author":"Meric-Bernstam F","year":"2024","unstructured":"Meric-Bernstam F, Hollebecque A, Furuse J, et al.. Safety profile and adverse event management for futibatinib, an irreversible FGFR1-4 inhibitor: pooled safety analysis of 469 patients. Clin Cancer Res. 2024, 30:1466-77. 10.1158\/1078-0432.CCR-23-2646","journal-title":"Clin Cancer Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/268115-response-of-fgfr-2-positive-adenoid-cystic-carcinoma-to-futibatinib-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T05:04:19Z","timestamp":1719551059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/268115-response-of-fgfr-2-positive-adenoid-cystic-carcinoma-to-futibatinib-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.63332","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,27]]}}}